Ca v 1.2 L-type calcium channels are essential in heart and smooth muscle contraction. Rat Ca v 1.2 gene contains 11 alternatively spliced exons (1a, 1, 8a, 8, 9 ⁎ , 21, 22, 31, 32, 32-6nt and 33) which can be assorted to generate a large number of functionally distinct splice variants. Until now, it is unknown whether the utilization of these alternatively spliced exons is altered in the hypertrophied hearts of hypertensive rats. By comparing the assortments of these 11 exons in full-length Ca v 1.2 transcripts derived from Spontaneously Hypertensive Rats (SHRs) and Wistar Kyoto Rats (WKYs) hearts, we found that the inclusion of Ca v 1.2 alternative exons was significantly different between the two rats both at individual loci and in combinatorial arrangements. Functional characterizations of three Ca v 1.2 channel splice variants that were identified to be significantly altered in SHR hypertrophied cardiomyocytes demonstrated distinct whole-cell electrophysiological properties when expressed in HEK 293 cells. Interestingly, aberrant splice variants which included or excluded both mutually exclusive exons 21/22 or exons 31/32 were found to be increased in hypertensive rats. Two aberrant splice variants that included both exons 21 and 22 were found to be unable to conduct currents even though they expressed proteins with the predicted molecular mass. Characterization of one of the aberrant splice variants showed that it exerted a dominant negative effect on the functional Ca v 1.2 channels when co-expressed in HEK293 cells. The altered combinatorial splicing profiles of Ca v 1.2 transcripts identified in SHR hearts provide a different and new perspective in understanding the possible role of molecular remodeling of Ca v 1.2 channels in cardiac hypertrophy as a consequence of hypertension.
Introduction
L-type (Ca v 1.2) voltage-gated calcium channels play essential roles in excitation-contraction coupling in heart and in maintaining the cardiac action potentials [1] [2] [3] [4] . Physiologically, the pore-forming Ca v 1.2 subunit has been shown to undergo extensive alternative splicing to generate many variations supporting distinctive and diverse functions and pharmacological properties [5] [6] [7] [8] [9] [10] [11] [12] [13] . Pathologically, Gidh-Jain et al. reported that there was a significant increase in mRNA level of the fetal isoform containing alternatively spliced exon 31, encoding for IVS3 segment of Ca v 1.2 subunit, in rodent non-infarcted myocardium during left ventricular remodeling [14] . Yang et al. also reported a switch in the distribution of the mutually exclusive exons 31/32 in human heart failure [15] . Recently, in human arterial vascular smooth muscle cells that have undergone atherosclerosis, Tiwari et al. reported that exons 9a (also named as exon 9 ⁎ ), 21/22, and 41A were altered [16] . These studies strongly suggest that alternative splicing of Ca v 1.2 subunit may be generally affected in pathological conditions.
The gene encoding human Ca v 1.2 subunit, CACNA1C, is huge and spans more than 500 kb in the human genome and contains at least 55 exons [17, 18] . Its rodent counterpart, Cacna1c, contains 52 exons and 11 of them are alternatively spliced exons (Fig. 1) . Technically, it is difficult to obtain a large number of full-length transcripts for this huge gene and to examine the changes of multiple alternatively spliced exons in each full-length cDNA clone. Therefore, while the changes in levels of inclusion of single alternatively spliced exons have been examined, the dynamic changes of multiple alternatively spliced exons in combination across the entire full-length Ca v 1.2 transcripts have not been investigated in pathological tissues. Here, by using long-range reverse transcriptase PCR (RT-PCR), hundreds of full-length Ca v 1.2 cDNA clones were generated from mRNA isolated from Spontaneously Hypertensive Rats (SHRs) hypertrophied hearts and normotensive Wistar Kyoto Rats (WKYs) hearts. These clones were then screened individually to profile their alternative splicing patterns.
Three different groups of full-length Ca v 1.2 cDNAs with distinct alternative exon combinatorial profiles were identified in rat heart and aorta in our previous study [19] . In heart, two distinct groups of Ca v 1.2 cDNAs designated heart 1a-50 and heart 1-50 were generated from alternate exon 1a and exon 1. In this study, we found that the alternative splicing patterns of the Ca v 1.2 gene in SHR hearts were significantly changed both at individual loci and in combinatorial arrangements in both groups of heart 1a-50 and heart 1-50 Ca v 1.2 cDNAs. Functional characterization of several Ca v 1.2 splice variants upregulated in hypertension by whole-cell patch clamp recordings demonstrated altered electrophysiological properties in comparison with the dominant splice variant from WKY controls.
Materials and methods

Measurement of blood pressures, body weight and heart weight of SHRs and WKYs
The blood pressures of SHRs and WKYs (the Animal Resource Center, Canning Vale, WA 6970, Australia) were measured by the tail-cuff method (ML125 system, Powerlab, ADInstruments). For assessment of cardiac hypertrophy, the whole animals, hearts and ventricles from SHRs and WKYs were weighed and the heart/body or left ventricle/body weight ratios were determined.
2.2.
Total RNA extraction, first strand Ca v 1.2 cDNA synthesis and real-time PCR to determine the ratios of exon 1a and exon 1 containing Ca v 1.2 cDNA Total RNA was extracted from left ventricles of five 4.5-month SHRs and five 4.5-month WKYs (3 males and 2 females in each groups) individually by RNeasy® Kits (QIAGEN Science, Maryland, USA). Reverse transcription for each rat RNA sample was separately carried out with SUPERSCRIPT II (Invitrogen, CA, USA). The primer for first strand Ca v 1.2 cDNA synthesis is complementary to 3′-untranslated regions of rat Ca v 1.2 gene (primer No. 6, supplemental Table 1 ). TaqMan quantitative real-time PCR for determining the ratios of exon 1a to exon 1 expression in rat ventricles were carried out as described in the previous study [19] . All the animal work has been approved by and done in accordance with the Institutional Animal Care and Use Committee (IACUC) guidelines of the National University of Singapore.
2.3. Generation of full-length heart 1a-50 and heart 1-50 Ca v 1.2 cDNAs from SHRs and WKYs
The PCR reactions were carried out to amplify the full-length rat Ca v 1.2 cDNAs from exon 1a to exon 50 (primer Nos. 5 and 6, Supplemental Table  S1 ) and from exon 1 to exon 50 (primer Nos. 7 and 8, Supplemental Table  S1 ) using total RNAs isolated from SHR or WKY rat ventricles ( Fig. 2A) . The sequences of all the primers used in this study are indicated in Supplementary Table S1 . Negative controls were done in parallel using RNA that was subject to reverse transcription reaction but without the addition of reverse transcriptase. PCR products from 5 SHRs and 5 WKYs with similar band intensities were pooled together, cloned into pCR®-XL-TOPO® vectors (Invitrogen™) and transformed into DH10B Escherichia coli. After screening approximately 3000 bacterial colonies by colony PCR method (exon 6-12, primer Nos. 13 and 14; and exon 44-47, primer Nos. 25 and 26, Supplemental Table S1 ), a total of 402 colonies (216 colonies from SHRs and 186 colonies from WKYs) representing 4 groups of full-length cDNAs were isolated. Each group of full-length Ca v 1.2 cDNAs contained 92 to 116 clones. These full-length Ca v 1.2 cDNAs were designated as SHR heart 1a-50, SHR heart 1-50, WKY heart 1a-50, and WKY heart 1-50 respectively.
2.4. Exon-specific PCR to identify inclusion or exclusion of alternatively spliced exons in Ca v 1.2 cDNA clones For each Ca v 1.2 cDNA clone in SHR heart 1a-50, SHR heart 1-50, WKY heart 1a-50, and WKY heart 1-50, eight PCR reactions were carried out to identify inclusion or exclusion of specific alternatively spliced exons in the clone. The detailed procedures of exon-specific colony PCR are presented in Supplementary Data. 3.1 ± 0.10 (n = 3) -3-month SHR 175 ± 6.9 (n = 5) ⁎⁎ 3.7 ± 0.12 (n = 3) ⁎ -4.5-month WKY 127 ± 3.8 (n = 5) 2.9 ± 0.11 (n = 5) 2.0 ± 0.26 (n = 5) 4.5-month SHR 187 ± 7.6 (n = 5) ⁎⁎ 3.6 ± 0.16 (n = 5) ⁎⁎ 2.7 ± 0.30 (n = 5) ⁎⁎ 8-month WKY 123 ± 6.3 (n = 6) 3.0 ± 0.05 (n = 6) -8-month SHR 193 ± 8.2 (n = 6) ⁎⁎ 3.6 ± 0.08 (n = 6) ⁎⁎ -Student's t-test was applied in comparing the blood pressures and ratios of heart weight-to-body weight of age-matched 3-, 4.5-and 8-month old SHRs and WKYs, and ratios of left ventricle weight-to-body weight of 4.5-month old SHRs and WKYs. n is the number of samples (rats or ventricles) tested. ⁎ , p b 0.05; ⁎⁎ , p b 0.01.
Data analysis for the proportions of individual Ca v 1.2 alternatively spliced exons and their combinations from SHRs and WKYs
The percentages of individual alternatively spliced exons, exon combinatorial profiles and their standard deviations were calculated based on the number of clones examined. A two-sided z-test was applied to compare the statistical significance between their proportions from SHRs and WKYs.
Single-cell reverse transcriptase-PCR
To verify that the recorded HEK293 cells in patch-clamp study were successfully transfected with both B2 and B31 splice variants, we did single-cell reverse transcriptase-PCR as described in the previous study [20] . Briefly, after a cell has been characterized electrophysiologically by the patch clamp method, the cell was collected into an individual vial containing reverse transcription reaction mix for first strand cDNA synthesis. Nested PCR reactions were employed to specifically amplify Ca v 1.2 amplicons for the identification of the presence of exons 21 and 22 in agarose gels.
The primers for 1st round of PCR are: RatE18F: 5′-ACACTGCAGGTGA-AGAGGATG-3′ and RatE25R: 5′-TTTCCCTTGAAGAGCTGGACC-3′. For nested PCR, the primers used were: RatE20F: 5′-TGCAGTGCCACCGCATT-GTC-3′ and RatE24R:
5′-TTGGCCCTGTTGATGGCCC-3′. PCR conditions were: denaturation at 95°C for 45 s, annealing at 55°C for 1 min and extension at 72°C for 1 min. A total of 40 cycles were performed for both the 1st round and nested PCR reactions. In the nested PCR reaction, the positive control PCRs were performed using B2 or B31 plasmid as templates. The expected sizes of the nested PCR products were 367 bp for B2 and 427 bp for B31.
Construction of full-length Ca v 1.2 splice variants into pcDNA3 vector
Four full-length rat Ca v 1.2 clones which represent the splice variants significantly changed in SHRs were constructed. These constructs were A4 (1a, 8a, −9 ⁎ , 22, 32-6nt, 33), A8 (1a, 8a, 9 ⁎ , 22, 32, 33), A5 (1a, 8a, −9 ⁎ , 21, 22, 32, 33) in pcDNA3.1-vector and B31 (1, 8a, −9 ⁎ , 21, 22, 32, 33) in pcDNA3 vector and their sequences were verified to be correct by DNA sequencing. The detailed procedures about the constructions are presented in Supplementary Data. The construction of B2 (1, 8a, −9 ⁎ , 22, 32, 33) in pcDNA3 was described in our previous study [19] .
Immunolabeling and Western blot analysis to detect the expressions of A5 and B31 splice variants in HEK 293 cells
The HEK 293 cells were transfected with A5 or B31 splice variants together with rat β 2a , α 2b δ, and T antigen using a calcium-phosphate mediated method and the immunostaining was performed as described previously [21] . Three primary antibodies (1:200) (Sigma-Aldrich, Inc. Saint Louis, Missouri, USA) used were either anti-exon 1a or anti-exon 1 antibodies, or anti-pan α1C antibody Fig. 2 . A. Exemplars of full-length PCR for heart 1a-50 and heart 1-50 from two 4.5-month SHR ventricles. Lanes 1 and 2 show the PCR results of heart 1a-50 reaction (primer Nos. 5 and 6; Supplemental Table S2 ) and lanes 3 and 4 show the PCR results of heart 1-50 reaction (primer Nos. 7 and 8, Supplemental Table S2 ). The expected PCR product is 6.5 kb for heart 1a-50 and 6.7 kb for heart 1-50. "−ve" indicates the negative control PCRs using corresponding RNA without reverse transcriptase treatment. B. Exon 8a specific PCR reactions (primer Nos. 9 and 10) were carried out in 4.5-month SHR and WKY heart 1a-50 cDNA containing colonies to identify the percentages of inclusions of exon 8a and exon 9 ⁎ . Upper panel is the colony PCR results for SHR heart 1a-50 cDNAs and lower panel is for WKY heart 1a-50 cDNAs. The sequencing result confirmed there was inclusion of exon 9 ⁎ in the higher band and without exon 9 ⁎ in the lower band. The negative controls using untransformed colonies as templates are indicated as "−ve". C. The percentages of nine individual alternatively spliced exons identified in 4.5-month SHR and WKY heart 1a-50 cDNAs were compared. n = 100 clones for SHR heart 1a-50 and n = 92 clones for WKY heart 1a-50. Exon 9 ⁎ was up-regulated approximately 3.7 times from 3% in WKYs to 11% in SHRs ( ⁎ , p b 0.05, z-test). The exact percentages of the alternatively spliced exons are presented in Supplemental Table S2 . Table 2 The proportions of splice variants in heart 1a-50 cDNAs from 4.5-month SHRs and WKYs WKY heart 1a-50 n = 92 SHR heart 1a-50 n = 100 The alternatively spliced exons included in a full-length clone are presented and "−" indicated the exons are excluded. The proportion of the same splice variant from SHRs and WKYs was compared by a two-sided z-test ( ‡, p b 0.05). n is the number of clones examined.
recognizing a common epitope in the II-III loop of Ca v 1.2. The secondary antibodies (1:500) were either goat anti-rabbit fluorescein isothiocyanate (FITC)-conjugated (for anti-exon 1a or anti-exon 1 antibodies) or goat anti-rabbit Rhodamine-conjugated antibodies (for anti-pan α1C antibody). The immunolabeled cells were visualized using a laser-scanning confocal microscope (Fluoview BX61; Olympus). For Western blot analysis, HEK293T cells were transfected with 10.2 μg Ca v 1.2 splice variants A1, A5, B2 and B31 respectively, together with 6.0 μg rat β 2a , 6.0 μg α 2b δ subunits using Lipofectamine™ 2000 kit (Invitrogen™) and grown for 48 h in 10-cm petri dishes. One fourth of the cells harvested were lysed with 150 μl Mem-PER® Reagent A (Pierce Biotechnology) supplemented with 34.8 μg/ml phenylmethylsulfonyl fluoride (PMSF). 8-16 μl of whole-cell lysates were applied to 4-20% Tris-Glycine Gel (Invitrogen™) and electrophoresed in Tris-Glycine SDS Running buffer. The proteins were transferred onto PROTRAN® nitrocellulose membranes (Whatman®, Germany). Anti-exon 1 or anti-pan α1C primary antibodies diluted at 1: 200 were applied to the membranes, followed by incubation with 1:10,000 secondary donkey anti-rabbit antibody conjugated with horseradish peroxidase (GE Healthcare). The western blots were developed using Femto Supersignal reagents (Pierce Biotechnology).
Whole-cell patch clamp electrophysiological recordings of rat Ca v 1.2 splice variants
Whole-cell patch clamp technique (MultiClamp 700B, Axon Instruments) was employed to study the electrophysiology of the transiently expressed Ca v 1.2 splice variants in HEK 293 cells. Approximately 1:1:1 molar ratios of cDNA for rat Ca v 1.2 splice variant, β 2a and α 2b δ were applied for transfection of HEK 293 cells. In the 35 mm petri dish, 1.65 μg of cDNA of rat Ca v 1.2 splice variants (A1, A4, A5, A8, B2 and B31 respectively, or both 1.65 μg B2 and 1.65 μg B31 in the dominant negative effect study) together with 1.25 μg of rat β 2a , 1.25 μg of α 2b δ, and 0.2 μg of TAG (T antigen) were transiently co-transfected into HEK293 cells (Human Embryonic Kidney 293 cells) using a calcium-phosphate mediated method. Transfected HEK293 cells were grown for 36-48 h in 5% CO 2 incubator at 37°C before patch clamp analysis. The current-voltage relationship, steadystate activation, steady-state inactivation recording and the data analyses were performed as described in our previous studies [18, 21] .
Electrophysiological recordings of I Ba in cardiac myocytes
isolated from SHR and WKY rats 2.10.1. Isolation of single cardiac myocytes 4.5-month SHR and WKY rats were injected intraperitoneally with 1000 IU heparin and euthanized in a CO 2 chamber. The heart was quickly removed and transferred to an ice-cold Tyrode solution. The aorta was cannulated and the heart was mounted on a Langendorff apparatus. The heart was perfused with prewarmed (at 37°C) and oxygenated Tyrode solution containing Protease Type XIV (Sigma P5147) Collagenase Type I (Sigma C0130) for 10 min until the heart was flaccid. The ventricles were dissected out, cut into small pieces, and gently stirred in the Tyrode solution. Isolated cells were filtered and maintained in an oxygenated KB solution on ice. Fig. 3 . Comparisons of the individual alternatively spliced exons in heart 1-50 cDNAs from 4.5-month SHRs and WKYs. Exon 8a was down-regulated 16% from 73% in WKYs to 57% in SHRs. On the contrary, exon 8 was up-regulated 16% from WKYs (27%) to SHRs (43%). n = 116 clones for SHR heart 1-50 and n = 94 clones for WKY heart 1-50. The changes were significantly different ( ⁎ , p b 0.05, z-test). Other exons were not significantly altered (Supplemental Table S2 ). Table 3 The proportions of splice variants in heart 1-50 cDNAs from 4.5-month SHRs and WKYs WKY heart 1-50 n = 94 SHR heart 1-50 n =116 The alternatively spliced exons included in a full-length clone are presented and "−" indicated the exons are excluded. The proportion of the same splice variant from SHRs and WKYs was compared by a two-sided z-test ( ‡, p b 0.05). n is the number of clones examined.
Electrophysiological and pharmacological studies for SHR and WKY cardiac myocytes
Voltage-clamp experiments for recording SHR and WKY cardiac myocytes were performed at room temperature (20-22°C), using the whole-cell patch clamp technique. Pipets with resistance of 1-2.5 MΩ were used and the series resistance and capacitive currents were compensated at 70%. To resolve the currents conducted through L-type calcium channels under voltage clamp, the bath contained (in mM) the following: N-methyl-D-glucamine (NMG), 155; HEPES, 10; MgCl 2 , 1; and Ba 2+ , 1.8 (pH 7.4 with MeSO 3 ). The internal solution contained (in mM): Cs-MeSO 3 , 120; CsCl, 5; HEPES, 10; EGTA, 10; MgCl 2 , 1; MgATP, 4; TEA-OH, 20; Sodium phosphocreatine, 5 and ryanodine (BIOMOL), 0.005 (pH 7.2 with CsOH). The current-voltage (I-V) relations were obtained from a holding potential of − 80 mV, 0.5 s depolarizing pulses to different membrane potentials (10 mV increments from −60 mV to +50 mV). The I-V curves were fitted by
where I is the test-pulse current, I max is the normalization peak current, G max = maximum conductance, E rev = reversal potential, V 1/2 = voltage at 50% of Ba 2+ current activation, and k I-V = slope factor. The steady-state inactivation curves were obtained from experiments by stepping from a holding potential of − 80 mV to a 30-ms normalizing pulse to 0 mV followed by a family of 5-s-long prepulses from −100 to 20 mV. A 104-ms test-pulse to 0 mV was recorded finally. Each test-pulse was normalized to the maximal current amplitude of the normalizing pulse. The data for inactivation curves were fitted with a simple Boltzmann function: 2 , where I is the testpulse current, I max is the normalization current, A 1 is initial current amplitude, A 2 is final current amplitude, V is the membrane potential of the conditioning pulse, V 1/2inact is the potential for half-inactivation, and k is the slope factor.
For pharmacological study, nifedipine (Sigma) was dissolved in Me 2 SO to make a 10 mM stock solution and stored at − 20°C. Nifedipine at 5 μM was freshly prepared in bath solution from stock. Cardiac myocytes from SHRs and WKYs were held at − 80 mV and then depolarized at 0 mV testing potential for 0.5 s. All experiments involving nifedipine were conducted as much as possible in the absence of light. Table 1 shows the pathophysiological characteristics of 3-, 4.5-and 8-month SHRs and WKYs such as blood pressures and heart weight-to-body weight ratios. SHRs had significantly higher (N 60 mmHg) systolic blood pressure (p b 0.01) and about 20% (p b 0.01) increase in the heart weight-to-body weight ratio relative to age-matched WKYs. In addition, left ventricle weight-to-body weight ratio was 2.7 ± 0.30 mg/g for 4.5-month SHRs and 2.0 ± 0.26 mg/g for 4.5-month WKYs representing a 35% increase in left ventricle weight-to-body weight ratio in SHRs than WKYs. These results confirmed that high blood pressure was fully developed and heart hypertrophy was initiated in 3-month SHRs and maintained up to 8 months in age.
Results
Evaluations of the pathophysiological characteristics of SHRs and WKYs
3.2.
Comparison of expressions of alternatively spliced exons at single locus or in combination in heart 1a-50 cDNAs Exon-specific colony PCRs and DNA sequencings were performed to identify the alternatively spliced exon at individual locus of each Ca v 1.2 full-length clone. Comparison of the expression levels of each splice locus between 4.5-month SHRs and WKYs showed that exon 9 ⁎ was significantly up-regulated from 3% in WKYs to 11% in SHRs (Fig. 2C) . The agarose electrophoresis gel shown in Fig. 2B revealed the larger PCR product containing the additional exon 9 ⁎ that was confirmed by DNA sequencing. The other 8 alternatively spliced exons were not significantly altered (Fig. 2C and Supplementary Table S2 ). In line with the result from our previous study [19] , there is no clone in the heart 1a-50 cDNAs containing exon 8. In addition, the rat counterparts of human alternate exon 10 ⁎ , exon 45 ⁎ and exon 45 have not been identified in rats thus far [6, 18, 22] , and we did not find these 3 exons in the 402 full-length rat Ca v 1.2 clones in this study.
Although at the single alternative splicing locus, only the proportion of exon 9 ⁎ showed a significant 3.7-fold increase in SHR heart, the combinatorial patterns of alternatively spliced exons of heart 1a-50 Ca v 1.2 channels were altered significantly in 4.5-month SHRs than in WKYs (Table 2 ). While exon combinatorial profile A1 showed a decrease of 17% in SHR hearts, A4 was up-regulated from 4% in WKYs to 12% in SHRs, and A8 was increased from 2% in WKYs to 11% in SHRs. All the changes in expression levels of A1, A4 and A8 were statistically significant (p b 0.05, z-test). In addition, there were 3 unusual alternatively spliced variants (aberrant variants) in heart 1a-50 that either exclude or include both mutually exclusive exons 21 and 22 (A3 and A5); or include another pair of mutually exclusive exons 31 and 32 (A13). The aberrant channels comprised 8% of Ca v 1.2 transcripts in WKY heart 1a-50 (A3 and A5) and 13% in SHR heart 1a-50 (A3, A5 and A13).
3.3.
Comparison of expressions of alternatively spliced exons at single locus or in combination in heart 1-50 cDNAs Only the proportions of mutually exclusive exons 8a and 8 were found significantly changed in heart 1-50 cDNAs ( Fig. 3 and Supplementary Table S2 ). However, the differences in exon combinatorial profiles between SHR and WKY heart 1-50 cDNAs were more pronounced and widespread (Table 3 ). The significant changes in alternative splicing profile were found in B2, a decrease of 10% in SHRs, and the expression of 6% of the novel B31 splice variant. It seemed the reduced proportion of B2 in SHRs was partially replaced by the increased percentage of B31 which aberrantly includes both exons 21/22 instead of exon 22 alone in B2. Overall, WKY heart 1-50 cDNAs comprised 19 splicing combinatorial profiles while SHR heart 1-50 cDNAs had 25 (Table 3) . Among these 25 combinatorial profiles, 15 were identical to those found in WKYs while 10 were unique to SHRs (B20, B24 and B31-B38; Table 3 ). In addition, SHR heart 1-50 contained 4 aberrant splicing combinatorial profiles which included both mutually exclusive exons 21 and 22 (B31, B36 and B38), or both mutually exclusive exons 31 and 32 (B35 and B36). The aberrant profiles accounted for about 9% of Ca v 1.2 transcripts in SHR heart 1-50 but none in WKY heart 1-50. Table S3 ). However, there was no significant difference in the ratios of expression of exon 1a/exon 1 of Ca v 1.2 transcripts obtained from 4 groups of ventricles of 3-month and 8-month SHRs or WKYs (p N 0.05; one-way ANOVA and Tukey test, Supplemental Table S3 ).
Distributions of 42 exon combinatorial profiles of Ca v 1.2 in SHR and WKY hearts
There were 42 distinct exon combinatorial profiles identified in heart 1a-50 and heart 1-50 cDNAs of 4.5-month SHRs and WKYs. A total of 30 profiles were identified in WKY hearts while 35 were found in SHRs. While 23 exon combinatorial profiles were identical in both WKYs and SHRs, 7 were unique in WKYs and 12 in SHRs (Fig. 4) . Hence, under hypertensive cardiac hypertrophy, certain splice loci varied significantly when analyzed individually but more obvious changes were observed in their full-length combinatorial profiles. Comparison of the percentages of splice variants containing (exons 21 +22) in the four full-length cDNAs groups from SHRs and WKYs. About 8% transcripts containing (exons 21 +22) were found in SHR heart 1-50, but no splice variants containing (exons 21 +22) were identified in WKY heart 1-50 ( ⁎⁎ , p b 0.01, z-test). In addition, higher (but not significantly different) percentages of splice variants containing (exons 21 +22) were found in SHR heart 1a-50 (10%) than in WKY heart 1a-50 (3%) (#, p = 0.064, z-test). 
Aberrant splice variants were mainly found in SHRs
In SHR hearts, there was an increase in the generation of aberrant splice variants which either included or excluded the pairs of mutually exclusive exons. Among the 42 exon combinatorial profiles, 7 were aberrant splice variants: A3, A5, A13, B31, B35, B36 and B38 (Tables 2 and 3 ). It is noteworthy that while all 7 aberrant splice variants were found in SHRs, only 2 were found in WKYs (A3 and A5) and there were no aberrant variants found in WKY heart 1-50. The aberrantly spliced Ca v 1.2 channels were increased from 8% in WKY heart 1a-50 to 13% in SHR heart 1a-50, and from none in WKY heart 1-50 to 9% in SHR heart 1-50. Interestingly, the predicted proteins encoded by these aberrant variants are all in-frame, without any premature stop codon suggesting that these aberrantly spliced mRNAs would survive the process of nonsense-mediated mRNA decay (NMD) [23, 24] and express their proteins. However, as shown later, two of the aberrant splice variants tested in this study demonstrated they were expressed but not functional when heterologously expressed in HEK 293 cells.
Out of the 7 aberrant splicing profiles, 4 of them (A5, B31, B36 and B38) contained both mutually exclusive exons 21 and 22 (Tables 2 and 3) . Interestingly, the proportions of aberrant Ca v 1.2 channels containing exons 21 and 22 were higher in both SHR heart 1a-50 and heart 1-50 cDNAs than in their WKY counterparts (Fig. 5) . SHR heart 1a-50 comprised about 10% of Ca v 1.2 channels containing exons 21 and 22 while WKY hearts only 3%. Similarly, SHR heart 1-50 contained significantly higher number of Ca v 1.2 channels including both exons 21 and 22 than in WKY controls (8% in SHRs to none in WKYs, p b 0.01). To evaluate whether such aberrant channels could be expressed and be functional, we transfected two of aberrant Table 4 . In contrast to A1, A4 and A8 splice variants which show recorded current traces upon different voltage stimulations, A5 and B31 which contain both mutually exclusive exons 21 and 22 showed no currents detected in I-V recording (n = 18 for A5; n = 26 for B31).
variants, A5 and B31, separately into HEK 293 cells. Immunolabelling of these transfected HEK 293 cells with either anti-exon 1a or anti-exon 1, or anti-pan α1C antibodies showed strong fluorescent signals detected on the plasma membrane while weaker punctated signals were detected in the cytoplasm (Fig. 6) , indicating that the proteins of A5 and B31 variants were expressed. Western blots using anti-exon 1 and anti-pan α1C antibodies confirmed that A5 and B31 aberrant variants were expressed (Fig. 7A) . Positive controls using the functional Ca v 1.2 cDNAs encoded by splice variants A1 and B2 verified the correct molecular size of the A5 and B31 aberrant proteins. However, A5 and B31 Ca v 1.2 channels expressed in HEK 293 cells were non-functional as no inward current was recorded from these variants when co-expressed with rat β 2a and α 2b δ (n = 18 for A5; n = 26 for B31). In contrast, I Ba was recorded from other Ca v 1.2 splice variants, A1, A4 and A8, in electrophysiological recordings performed in parallel (Fig. 7B) .
Distinctive current-voltage relationships and steady-state activation of Ca v 1.2 splice variants
To assess possible functional importance in the changes of proportions of Ca v 1.2 splice variants, we evaluated the electrophysiological properties of the other three splice variants that also showed significant changes in heart, namely A1, A4 and A8. We limited our investigations for the following three Table 4 Parameters of current-voltage relationships, steady-state activation and steadystate inactivation of A1, A4 and A8 splice variants Table 4 . Superimposition of activation and SSI curves indicated the theoretical "window currents" [25, 42] for the 3 variants. D. Plotting the negative product of activation and SSI curves at different membrane potentials to show the values of "window currents" for A1, A4 and A8 splice variants.
reasons: (1) the heart 1a-50 represents 13.4-to 16-fold more transcripts than the heart 1-50 (Supplemental Table S3 ), hence the changes in A1, A4 and A8 in heart 1a-50 would represent the dominant changes observed in hypertensive hearts; (2) the biophysical property of B2 has been evaluated in pharmacological studies by others [9, 10] ; and (3) the A5 and B31 are aberrant variants shown to be not functional. Whole-cell patch clamp electrophysiological recordings showed that the I-V relations of the splice variants A4 and A8 were hyperpolarized shifted by about 5 mV and 6.4 mV when compared with the heart 1a-50 dominant variant A1 (Fig. 7A) . Both V 1/2 values of A4 and A8 splice variants were significantly different from that of A1 variant (p b 0.05), while the reversal potentials for all the 3 splice variants were similar (Table 4) .
To further examine the extent by which exon combinatorial profiles may affect the voltage-dependence of activation, we performed tail-current analysis of the activation process. The V 1/2act values were significantly shifted in the hyperpolarized direction by 7.1 mV for A4 and by 8.7 mV for A8 than the dominant A1 variant ( Fig. 8 and Table 4 ). However, the steady-state inactivation properties of A4 and A8 splice variants exhibited no significant difference in V 1/2inact when compared to A1 (Fig. 8 and Table 4 ). To determine whether the "window currents" of A4 and A8 might be different to A1 due to their hyperpolarized shifts in V 1/2act values but not to changes in V 1/2inact values, we calculated the theoretical "window currents" of A1, A4 and A8 by multiplying their activation curve values by their corresponding inactivation curve values [25] [26] [27] . A8 exhibited a larger window current (3% of its peak I Ba ) than A1 (1% of its peak I Ba ) due to the hyperpolarized shift in V 1/2act values by ∼8.7 mV (Fig. 8C and D) . However, the window currents of A4 and A1 were similar (1% of their relative peak I Ba ) as the foot regions of their activation curves were largely overlapping ( Fig. 8B and D) .
Dominant negative effect exerted by aberrant splice variant B31 on B2 function
The expression of aberrant non-functional Ca v 1.2 variants such as A5 and B31 suggests that RNAs or/and proteins of these aberrant variants may affect the expression of functional channels in a dominant negative manner through competition for factors involved in Ca v 1.2 channels transcription, translation, protein folding, transport, phosphorylation or by other physiological regulatory mechanisms. To test this hypothesis, we examined the tail-current densities of the normal B2 variant when it was transfected alone or co-transfected with B31 into HEK293 cells. As shown in Fig. 9A , the current density obtained from tailcurrent recording in HEK293 cells co-transfected with (B2 + B31), rat β 2a and α 2b δ subunits were markedly reduced when compared to the control group in which HEK293 cells were transfected with B2, rat β 2a and α 2b δ subunits. The single-cell RT-PCR from the recorded HEK293 cells confirmed that both B2 and B31 constructs were successfully co-transfected into the cells (Fig.  9B) . Therefore, it is obvious that aberrant splice variant B31 exerted the dominant negative effect on normal B2 variant in the heterologous HEK293 cells expression system.
Electrophysiological and pharmacological studies for SHRs and WKYs cardiac myocytes
L-type calcium channels in heart ventricles consist of mainly the Ca v 1.2 calcium channels and a very small portion of the Ca v 1.3 channels [28, 29] . To examine the behaviors of the overall Ca v 1.2 channels consisting of all the existing splice variants in heart muscle cells, we examined the electrophysiological properties of L-type calcium channels in cardiac myocytes isolated from the left ventricles of 4.5-month SHR and WKY rats. Our results showed that generally the L-type calcium channels in cardiac myocytes from these two rats displayed modest differences in the current-voltage relationships and in the voltage-dependent steady-state inactivation properties. The values of V 1/2 and V 1/2inact were − 26.38 mV and − 36.43 mV for SHRs, and − 30.16 mV and −38.87 mV for WKYs ( Fig. 10 and Table 5 ). Similarly, the sensitivity of the L-type calcium channel currents blockade by nifedipine (5 μM) recorded at a holding potential of −80 mV was not significantly different. The average (Fig. 10C ).
Discussion
This study revealed the complex alterations in the alternative splicing of Ca v 1.2 channels in SHR cardiac hypertrophy. Previous studies have reported that dopamine receptors, sarco/ endoplasmic reticulum Ca 2+ ATPases and plasma membrane Ca 2+ ATPases genes were subjected to either exon-switching or alteration in the expression level of the isoforms under hypertensive conditions [30] [31] [32] . Here, we further demonstrated the dynamic changes in the alternative splicing profiles of Ca v 1.2 channels both at single loci and in their combinatorial profiles. Currently, the technical limitation in isolating and sequencing one-molecule Ca v 1.2 variant protein (∼ 240 kDa) precludes the determination of their individual molecular identities in native tissues. Hence the combinatorial splicing profiles of Ca v 1.2 transcripts identified in this study will provide an essential alternative for understanding their proteomic diversity in SHR hypertrophied hearts.
Implications of altered functional characteristics of dominant Ca v 1.2 splice variants
It has been reported that the promoter for transcribing exon 1a is activated mainly in neonatal cardiomyocytes but not in cardiac fibroblasts, H9C2 cells, or human aorta-vascular smooth muscle [33] [34] [35] . Moreover, heart 1a-50 Ca v 1.2 channels were also reported to be expressed in isolated cardiac myocytes [36] . These studies suggest that heart 1a-50 Ca v 1.2 channels are expressed in cardiomyocytes. Previous studies have shown that exon 9 ⁎ is rarely expressed in rat ventricles [21] and is undetectable in human atrial cardiomyocytes [12] . In agreement with these reports, we found that exon 9 ⁎ represented only 3% in heart 1a-50 in WKY but the expression was increased to 11% in SHR heart 1a-50. Consequently, the full-length splicing combinatorial profile A8 containing exon 9 ⁎ was increased from 2% in WKY heart 1a-50 to 11% in SHR heart 1a-50. The A8 variant encoding Ca v 1.2 channels that displayed larger window currents and activation at more hyperpolarized voltages may potentially allow for a larger driving force to increase magnitude of I CaL which is often seen in hypertrophied cardiac myocytes [37] . In SHR heart 1a-50, the combined increase in expression of A4 and A8 was 17% while correspondingly A1 decreased by 17%. The 5-6.4 mV hyperpolarized shift in the I-V relations attributable to A4 and A8, and compared to A1, may result in a predicted overall small hyperpolarized shift. However, we did not observe the same hyperpolarized shift in native cardiac myocytes of SHR cardiac myocytes but instead a small ∼ 3.8 mV depolarized shift in I-V was observed over WKYs, while the I-V relationships of the Ca v 1.2 channels recorded in 6 month old SHR and WKY cardiomyocytes were similar [38] . Whether the remodelling of the Ca v 1.2 channels generating different subsets of combinatorial profiles may vary over the time course of the development of cardiac hypertrophy or heart failure would require much more detailed and careful molecular and electrophysiological experimentations. The opposite shifts in I-V relationships of the A4 and A8 variants to what was actually recorded in ventricular muscles suggest a possible mechanism to remodel Ca v 1.2 channels to compensate for unknown factors that depolarized shift the activation potential of the Ca v 1.2 calcium channels.
As discussed in our previous study [19] , heart 1-50 cDNAs could be derived from multiple cell types like cardiomyocytes, cardiac fibroblasts, and vascular smooth muscle cells and its functional importance can be implied from the classic Timothy syndrome caused by the mutation in exon 8 which is named exon 8A by Splawski et al. in their report [39] . Two changes in SHR heart 1-50 cDNAs should be highlighted. First, the 16% upregulation in exon 8 may affect the pharmacological effects of calcium channel blocker dihydropyridines (DHPs) on these subset channels as it was previously reported that exon 8a and exon 8 regulated the sensitivity of Ca v 1.2 channels to DHPs differently [9] . Interestingly, a recent report also showed that two out of 39 human ischemic hearts examined showed unusually higher expression level of exon 8 in the left ventricles [17] . However, we did not observe a significant difference in nifedipine blockade when we applied the 5 μM nifedipine on native cardiac myocytes isolated from SHR or WKY rats (Fig.  10C) . One possible reason is that the change in exon 8 expression was mainly from other heart cells like cardiac fibroblasts or vascular smooth muscle cells rather than cardiac myocytes. Another reason is likely that the overall level of exon 8 expression is very low as the change was observed in the heart 1-50 cDNAs. This group of exon 1-containing Ca v 1.2 channel cDNAs accounted for less than 7% of the total Ca v 1.2 cDNAs (Supplementary Table S3 ). Secondly, Ca v 1.2 channels containing both exons 21 and 22 were found to be significantly increased in SHR heart 1-50 cDNAs and as a result, the aberrant splice variant B31 was generated in SHRs but not in WKYs. It will be interesting to identify which cells are involved in the upregulation of B31 expression in SHRs. Future experiments carried out on the isolated cardiomyocytes, cardiac fibroblasts, and vascular smooth muscle cells will be helpful in providing an explanation.
Relevance of aberrant Ca v 1.2 alternative splicing isoforms to cardiac hypertrophy
Interestingly, the aberrantly spliced Ca v 1.2 channels were increased from 8% in WKY heart 1a-50 to 13% in SHR heart 1a-50, and from none in WKY heart 1-50 to 9% in SHR heart 1-50, and two of them, A5 and B31, demonstrated to form nonfunctional channels. One possible explanation for their nonfunctionality is that the topology of the channels may have been affected by the inclusion of both exons 21 and 22. Exon 21 or exon 22 forms the transmembrane IIIS2 segment and two copies of these may invert the topology of the downstream sequences. In addition, we showed that B31 exerted dominant negative effects on normal B2 variant when they are co-expressed in HEK293 cells. It is not clear what the mechanism is for this dominant negative effect. The RNAs and proteins of aberrant variants would compete with normal variants during the whole process for functional Ca v 1.2 channel synthesis, from transcription, translation to protein modification. Another explanation is that the B31 aberrant channels directly compete for the β and α 2 δ subunits as they have been shown to be expressed on the cell surface and they produce robust amount of proteins as detected by Western blot analysis. However we cannot exclude that the unfolded protein response system may have been activated if the B31 aberrant channels behaved like truncated calcium channels [40, 41] . The overall effect of these aberrant channels is likely to act in a dominant negative manner in vivo to homeostatically regulate the expression level and activities of Ca v 1.2 channels in the hypertrophied cardiomyocytes.
